NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

REGENXBIO Inc. (RGNX) Stock Analysis

REGENXBIO Inc. (RGNX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

RGNX

$8.94

−$0.26 (−2.83%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare RGNX with… →

RGNX Key Statistics

As of Sep 4, 2026
Trading
Open
$9.09
Previous Close
$9.20
Day's Range
8.86–9.22
52-Week Range
5.46–16.19
Volume
1.07M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.93
Valuation
Market Cap
$590.16M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
3.38
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.78
Financials (FY)
Revenue (FY)
$170.44M+104.54%
Net Income (FY)
−$193.88M
Profit marginThe share of revenue left as profit after all costs and taxes.
−112.58%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
66.01M
1-Year Return
−5.10%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
1.97M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

RGNX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−37.92%
2025+86.29%
2024−56.94%
2023−20.86%
2022−30.64%
2021−27.91%
2020+10.72%
2019−2.34%
2018+26.17%
2017+79.25%
2016 (partial year)+95.68%

As of September 4, 2026.

RGNX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$170.44M−$193.88M−113.8%
2024$83.33M−$227.10M−272.5%
2023$90.24M−$263.49M−292.0%
2022$112.72M−$280.32M−248.7%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$170.44M$150.14M−$161.20M−$193.88M−113.8%
2024$83.33M$49.76M−$231.25M−$227.10M−272.5%
2023$90.24M$53.03M−$268.13M−$263.49M−292.0%
2022$112.72M$58.18M−$262.88M−$280.32M−248.7%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

RGNX Valuation vs Biotechnology Median

Median of 656 stocks
MetricRGNXBiotechnology medianvs median
P/S ratio3.3815.260.2x the median
Profit margin−112.58%0.00%112.6 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 11 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

REGENXBIO Inc. (RGNX) is capitalised at $590.16M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 371.

RGNX last closed at $8.94 on September 4, 2026. That is −$0.26 (−2.83%) against the previous close. Over the past 52 weeks the price has ranged from $5.46 to $16.19. The latest close sits 63.89% above that 52-week low.

Financial Health

In fiscal 2025, REGENXBIO Inc. reported revenue of $170.44M. That is +104.54% against the prior fiscal year, when revenue was $83.33M. The same year closed with a net loss of $193.88M. Profit margin runs at −112.58%. That is 112.6 percentage points below the Biotechnology median of 0%. Earnings per share on a trailing basis come to −3.78.

Across the 4 fiscal years on file, revenue moves from $112.72M in 2022 to $170.44M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 3.38 times revenue. On price-to-sales that is 0.2 times the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

Beta against the wider market is reported at 0.93. Annualized volatility over the trailing 10 years is 70.01%. The trailing one-year price return is −5.10%. Across 10 years the annualized return works out at −2.77%.

Growth & Income

The record shows no dividend for RGNX.

Across the complete calendar years on file, 2025 returned +86.29% and 2024 returned −56.94%. Of the 9 complete calendar years on file, 4 finished higher. So far in 2026 the price is −37.92%.

Peer Comparison

REGENXBIO Inc. (RGNX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
REGENXBIO Inc. RGNX $590.16M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. REGENXBIO Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About REGENXBIO Inc.

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

Visit website →